KYORIN Pharmaceutical Co.,Ltd. [4569.T]
TOKYO, Apr 24 (Pulse News Wire) – Kyorin Pharmaceutical CO.,LTD. (4569.T) signed a basic agreement today to transfer its generic drug business and production facilities to a joint venture firm called Medical Innovation Corporation (tentative name).
The move aligns with the company's long-term vision to focus on innovative pharmaceuticals while addressing supply issues in the generic drug sector. Under the agreement, KYORIN’s subsidiary Kyorin Remedio and two production plants—Kyorin Pharmaceuticals’ Takao Plant and Inaba Plant—will be transferred to Medical Innovation Corporation, which is led by Dai To Co., Ltd. and backed by two additional investors.
The purpose of this transition is to enhance sustainable supply systems and improve operational efficiency within the generic drug industry. Key details of the deal include: - Transfer Date: Scheduled for April 1, 2027 - Final Agreement Signing: Expected by September 2026 - Facilities Involved: Kyorin Remedio, Takao Plant, and Inaba Plant - Capital Investment: Kyorin Remedio’s capital is ¥100 million Kyorin Remedio, established on October 15, 1947, had revenues of ¥32.92 billion in fiscal 2023, rising to ¥34.28 billion in fiscal 2025. The company reported net profits of ¥528 million in fiscal 2023, increasing to --¥519 million in fiscal 2025.
KYORIN expects to finalize negotiations by the end of September 2026 and will disclose any significant impacts on group performance once evaluated.
🟡 Confidence: Standard AI-translated content.